Effect of rosuvastatin on concentrations of plasma lipids, urine and plasma oxidative stress markers, and plasma high-sensitivity C-reactive protein in hypercholesterolemic patients with and without type 2 diabetes mellitus: A 12-week, open-label, pilot study

Current Therapeutic Research - Clinical and Experimental

Volumn 70, Issue 6, 2009, Pages 439-448

  Yoshino, Gen ^a   Tanaka, Manabu ^b   Nakano, Saburo ^a   Matsumoto, Tomoko ^a   Kojima, Masato ^a   Murakami, Eiichi ^b   Morita, Toshisuke ^a  

^a TOHO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b TOHO UNIVERSITY   (Japan)

Author keywords

hs CRP; hypercholesterolemia; oxidative stress; rosuvastatin; type 2 diabetes

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; 8 ISOPROSTAGLANDIN F2 ALPHA; ALANINE AMINOTRANSFERASE; ANTIDIABETIC AGENT; C REACTIVE PROTEIN; CHOLESTEROL; CREATINE KINASE; CREATININE; FREE RADICAL; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; REACTIVE OXYGEN METABOLITE; ROSUVASTATIN; TRIACYLGLYCEROL;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; CREATININE BLOOD LEVEL; DIET THERAPY; DISEASE ASSOCIATION; DRUG BLOOD LEVEL; DRUG TOLERABILITY; EXERCISE; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; INFORMED CONSENT; INTERVIEW; LABORATORY TEST; LIPID BLOOD LEVEL; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; OXIDATIVE STRESS; PILOT STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; THERAPY EFFECT; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; URINE;

EID: 74549131897     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.curtheres.2009.12.003     Document Type: Article

References (36)

1. Grundy S.M., Cleeman J.I., Merz C.N., et al., National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program, Adult Treatment Panel III guidelines [published correction appears in Circulation. 2004;110:763]. Circulation 110 (2004) 227-239
2. Turner R.C., Millns H., Neil H.A., et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ. 316 (1998) 823-828
3. Nakamura H., Arakawa K., Itakura H., et al., MEGA Study Group. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): A prospective randomized controlled trial. Lancet 368 (2006) 1155-1163
4. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet 360 (2002) 7-22
5. LaRosa J.C., Grundy S.M., Waters D.D., et al., Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 352 (2005) 1425-1435
6. Shepherd J., Cobbe S.M., Ford I., et al., West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 333 (1995) 1301-1307
7. Sacks F.M., Moyé L.A., Davis B.R., et al. Relationship between plasma LDL concentration during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial. Circulation 97 (1998) 1446-1452
8. Schönbeck U., and Libby P. Inflammation, immunity, and HMG-CoA reductase inhibitors: Statins as antiinflammatory agents?. Circulation 109 Suppl 1 (2004) II18-II26
9. Takemoto M., and Liao J.K. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arterioscler Thromb Vasc Biol. 21 (2001) 1712-1719
10. Rikitake Y., Kawashima S., Takeshita S., et al. Anti-oxidative properties of fluvastatin, an HMG-CoA reductase inhibitor, contribute to prevention of atherosclerosis in cholesterol-fed rabbits. Atherosclerosis 154 (2001) 87-96
11. Teramoto T., and Watkins C. Review of efficacy of rosuvastatin 5 mg. Int J Clin Pract. 59 (2005) 92-101
12. Steinbrecher U.P., Parthasarathy S., Leake D.S., et al. Modification of low density lipoprotein by endothelial cells involves lipid peroxidation and degradation of low density lipoprotein phospholipids. Proc Natl Acad Sci U S A. 81 (1984) 3883-3887
13. Steinberg D., Carew T.E., Fielding C., et al. Lipoproteins and the pathogenesis of atherosclerosis. Circulation 80 (1989) 719-723
14. Salonen J.T., Ylä-Herttuala S., Yamamoto R., et al. Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet 339 (1992) 883-887
15. Alberti A., Bolognini L., Macciantelli D., and Caratelli M. The radical cation of N,N-diethylparaphenylendiamine: A possible indicator of oxidative stress in biological samples. Res Chem Intermed 26 (2000) 253-267
16. Davi G., Ciabattoni G., Consoli A., et al. In vivo formation of 8-iso-prostaglandin F2alpha and platelet activation in diabetes mellitus: Effects of improved metabolic control and vitamin E supplementation. Circulation 99 (1999) 224-229
17. Erhola M., Toyokuni S., Okada K., et al. Biomarker evidence of DNA oxidation in lung cancer patients: Association of urinary 8-hydroxy-2'-deoxyguanosine excretion with radiotherapy, chemotherapy, and response to treatment. FEBS Lett. 409 (1997) 287-291
18. Tsai E.C., Hirsch I.B., Brunzell J.D., and Chait A. Reduced plasma peroxyl radical trapping capacity and increased susceptibility of LDL to oxidation in poorly controlled IDDM. Diabetes 43 (1994) 1010-1014
19. Jonasson L., Holm J., Skalli O., et al. Regional accumulations of T cells, macrophages, and smooth muscle cells in the human atherosclerotic plaque. Arteriosclerosis 2 (1986) 131-138
20. Ridker P.M., Cushman M., Stampfer M.J., et al. Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation 97 (1998) 425-428
21. Ridker P.M., Rifai N., Pfeffer M.A., et al., Cholesterol and Recurrent Events (CARE) Investigators. Long-term effects of pravastatin on plasma concentration of C-reactive protein. Circulation 100 (1999) 230-235
22. Adam O., and Laufs U. Antioxidative effects of statins. Arch Toxicol 82 (2008) 885-892
23. Proudfoot J., Barden A., Mori T.A., et al. Measurement of urinary F(2)-isoprostanes as markers of in vivo lipid peroxidation-A comparison of enzyme immunoassay with gas chromatography/ mass spectrometry. Anal Biochem. 272 (1999) 209-215
24. Ledue T.B., Weiner D.L., Sipe J.D., et al. Analytical evaluation of particle-enhanced immunonephelometric assays for C-reactive protein, serum amyloid A and mannose-binding protein in human serum. Ann Clin Biochem 35 (1998) 745-753
25. The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA. 251 (1984) 365-374
26. Patrono C., and FitzGerald G.A. Isoprostanes: Potential markers of oxidant stress in atherothrombotic disease. Arterioscler Thromb Vasc Biol. 17 (1997) 2309-2315
27. Praticò D., Barry O.P., Lawson J.A., et al. IPF2alpha-I: An index of lipid peroxidation in humans. Proc Natl Acad Sci U S A. 95 (1998) 3449-3454
28. Reilly M.P., Pratico D., Delanty N., et al. Increased formation of distinct F2 isoprostanes in hypercholesterolemia. Circulation 98 (1998) 2822-2828
29. Ohashi N., and Yoshikawa M. Rapid and sensitive quantification of 8-isoprostaglandin F2alpha in human plasma and urine by liquid chromatography-electrospray ionization mass spectrometry. J Chromatogr B Biomed Sci Appl. 746 (2000) 17-24
30. Kuboki K., Terada E., and Yoshino G. Two oxidative stress markers and high-sensitivity C-reactive protein in patients with type 2 diabetes-effect of pioglitazone treatment. In: Ford A.M. (Ed). Focus on Diabetes Mellitus Research (2005), Nova Biomedical Books, New York, NY 17-32
31. Praticò D., Iuliano L., Mauriello A., et al. Localization of distinct F2-isoprostanes in human atherosclerotic lesions [published correction appears in J Clin Invest. 1997;100:2637]. J Clin Invest. 100 (1997) 2028-2034
32. Yoshino G., Hirano T., Kazumi T., et al. Fluvastatin increases LDL particle size and reduces oxidative stress in patients with hyperlipidemia. J Atheroscler Thromb 10 (2003) 343-347
33. Adachi S., Kawamura K., and Takemoto K. Oxidative damage of nuclear DNA in liver of rats exposed to psychological stress. Cancer Res. 53 (1993) 4153-4155
34. Kuboki K., Iso K., Murakami E., et al. Effect of valsartan on inflammatory and oxidative stress markers in hypertensive, hyperglycemic patients: An open-label, prospective study. Curr Ther Res Clin Exp. 68 (2007) 338-348
35. Hayashi T., Morishita Y., Hayashi I., et al. Rapid and multi-sample determination of reactive oxygen species in human sera [in Japanese]. JJCLA. 30 (2005) 216-220
36. Saisho Y., Komiya T., and Hirose H. Effect of valsartan, an angiotensin II receptor blocker, on markers of oxidation and glycation in Japanese type 2 diabetic subjects: Blood pressure-independent effect of valsartan. Diabetes Res Clin Pract 74 (2006) 201-203